MedPath

German Registry for Transcatheter Tricuspid Valve Interventions

Recruiting
Conditions
Tricuspid Regurgitation
Tricuspid Valve Insufficiency
Heart Valve
Registration Number
NCT04653428
Lead Sponsor
LMU Klinikum
Brief Summary

Multicentre observational study of patients with severe tricuspid regurgitation and interventional treatment.

Detailed Description

Severe tricuspid regurgitation occurs in around 1.5 % of men and 5.6 % of women and it is associated with significant morbidity and mortality. Current guidelines recommend cardiac surgery, especially in those patients who are undergoing left side valve surgery. Nevertheless many patients are not eligible for surgical tricuspid valve repair due to an high risk of mortality. Therefore interventional devices for treatment of tricuspid regurgitation have been established to offer these patients an alternative treatment option. The aim of this study is to analyse the success and saftey aspects of different interventional repair techniques for severe tricuspid regurgitation. Therefore in this prospectively designed observational study clinical, echocardiographic and laboratory parameters will be collected.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Interventional treatment of severe tricuspid regurgitation (isolated or in combination with another interventional treatment) with a CE certified product for tricuspid valve repair
  • Informed consent corresponding to criteria of Good Clinical Practice and the decleration of Helsinki as well as to standards of the local ethic commission.
Exclusion Criteria
  • No agreement to participation
  • Age < 18 years

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
All-cause death and heart failure hospitalisation1 year

All-cause death and heart failure hospitalisation 1 year after transcatheter tricuspid valve treatment (TTVT)

Secondary Outcome Measures
NameTimeMethod
Change of 6-minute walking distance test after transcatheter tricuspid valve treatment (TTVT)up to 5 years

Assessed by standardized protocol testing 6-minute walking distance

Change of NYHA classification after transcatheter tricuspid valve treatment (TTVT)up to 5 years

NYHA classification I, II, III or IV

Change of NT-proBNP after transcatheter tricuspid valve treatment (TTVT)up to 5 years

N-terminal pro Brain Natriuretic Peptide (NT-proBNP) in pg/ml

Procedural success after transcatheter tricuspid valve treatment (TTVT)At the day of discharge after transcatheter tricuspid valve treatment (TTVT)

Procedural success is defined as a reduction of the tricuspid regurgitation to at least grade 2+ achieved by interventional treatment

All-cause death and heart failure hospitalisation (long-term)up to 5 years

Long-term all-cause death and heart failure hospitalisation after transcatheter tricuspid valve treatment (TTVT)

Change of quality of life after transcatheter tricuspid valve treatment (TTVT)up to 5 years

Quality of life is assessed by standardized questionnaires including the Minnesota Living with Heart Failure Questionnaire

All-cause death and heart failure hospitalisation (short-term)30-90 days

Short-term all-cause death and heart failure hospitalisation after transcatheter tricuspid valve treatment (TTVT)

Change of cardiopulmonal symptoms after transcatheter tricuspid valve treatment (TTVT)up to 5 years

Assessment for cardiopulmonal symptoms include edema scaling

Change of tricuspid regurgitation after transcatheter tricuspid valve treatment (TTVT)up to 5 years

Assessed by echocardiography, tricuspid regurgitation graded on a 4-grade scale.

Trial Locations

Locations (1)

Klinikum der LMU Muenchen

🇩🇪

Munich, Germany

© Copyright 2025. All Rights Reserved by MedPath